STOCK TITAN

U.S. Physicians Can Now Order Lucira Health Self-Administered, Lab Quality, COVID-19 Molecular Test for Home or Office

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
covid-19
Rhea-AI Summary

Lucira Health, Inc. (Nasdaq: LHDX) has announced the availability of its COVID-19 All-In-One Test Kits for U.S. healthcare providers. These FDA-authorized kits can provide results in under 30 minutes and are designed for both in-office and at-home use. Each kit costs $50 and is manufactured in the U.S., featuring a simple process for self-administration. Clinical trials indicate accuracy comparable to leading molecular assays, with 94% agreement for positive results and 98% for negative ones. The kits are aimed at facilitating quicker COVID-19 testing amid ongoing concerns.

Positive
  • FDA authorized COVID-19 All-In-One Test Kits available for order by U.S. physicians.
  • Tests can provide results in 11 minutes (positive) and 30 minutes (negative).
  • High sensitivity compared to traditional rapid antigen tests.
  • 94% agreement with leading molecular assay in clinical trials.
Negative
  • None.

Lucira Health, Inc. (Nasdaq: LHDX), today announced that U.S. physicians and healthcare providers can now order Lucira COVID-19 All-In-One Test Kits online from lucirahealth.com. This U.S. made and manufactured product is the first FDA authorized, prescription, molecular diagnostic test for COVID-19 that can be self-administered in a physician’s office, or used by patients at home. Each single-use test kit costs $50 and contains everything needed to conduct one COVID-19 test. It can produce a positive result within 11 minutes, or a negative result within 30 minutes.

Lucira COVID-19 All-In-One Test Kits can be self-administered in a physician’s office, or used by patients at home. (Photo: Business Wire)

Lucira COVID-19 All-In-One Test Kits can be self-administered in a physician’s office, or used by patients at home. (Photo: Business Wire)

“Physicians in private practice like myself have been overwhelmed by patients suspected of having COVID-19. All of us want fast, accurate test results in minutes, not days. The Lucira test makes that possible,” said Dr. Neeraj Kochhar, M.D., a family medicine specialist in Los Gatos, California.

U.S. physicians who order the test can use it in their offices, or provide it to patients suspected of having COVID-19. It is the first molecular test kit that can be self-administered, and was designed and tested for use at home without requiring any telehealth or supervised assistance.

Featuring an easy-to-use ‘swab, stir and detect’ design, clinical trials showed 100% of patients were successfully able to perform the Lucira test in about two minutes. Labs currently take two to fourteen days to generate similarly accurate test results.

High sensitivity molecular tests like Lucira’s are significantly more sensitive than “rapid” antigen tests which do not work as well at very low viral loads. The result is they can miss active COVID-19 infections. Molecular tests such as PCR (polymerase chain reaction) and Lucira’s test are considered diagnostically definitive, unlike antigen tests which can require confirmatory molecular testing.

In a Community Trial setting, Lucira test results were compared with the Hologic Panther Fusion, which is considered one of the current market-leading molecular assays in an FDA published study because of its low Limit of Detection. The comparative positive results agreed 94% of the time across all samples, and 100% of the time excluding samples containing very low levels of virus (at or below 37.5 Ct). The negative results agreed 98% of the time across all samples.

Portable, accurate test

Lucira’s COVID-19 All-In-One Test Kit fits in the palm of a hand, extracts genetic material from the virus and amplifies it similar to PCR lab tests.

Each Lucira test kit contains everything needed to run one COVID-19 test: Users get the test device, two AA batteries, sample vial, swab and simple instructions. The batteries are inserted in the device and the sample vial is placed in the test unit. Next, the user opens the test swab packet and rotates the swab in each nostril five times. The swab is then stirred in the sample vial, and then pressed down in the test unit to start the test. The “ready” light will blink until a “positive” or “negative” green light is illuminated within 30 minutes. For guidance on care and public health reporting, patients will contact or report their test results to the healthcare provider that prescribed the test.

Lucira Health

Lucira Health a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. Lucira has developed a testing platform that produces centralized-laboratory-accurate molecular testing in a single-use and consumer-friendly test kit that is powered by two AA batteries and fits in the palm of a hand. Lucira designed its test kits to provide accurate, reliable and on-the-spot molecular test results anywhere and at any time. The LUCIRA COVID-19 All-In-One Test Kit is designed to provide a clinically relevant COVID-19 result within 30 minutes from sample collection.

FAQ

What is the Lucira COVID-19 All-In-One Test Kit's cost and where can it be ordered?

The Lucira COVID-19 All-In-One Test Kit costs $50 and can be ordered online by U.S. physicians and healthcare providers.

How quickly can the Lucira COVID-19 test provide results?

The test can provide a positive result within 11 minutes and a negative result within 30 minutes.

What distinguishes the Lucira test from rapid antigen tests?

Lucira's molecular test is more sensitive and capable of detecting lower viral loads compared to rapid antigen tests.

What were the accuracy results of the Lucira COVID-19 test in clinical trials?

In clinical trials, the Lucira test had a 94% agreement rate for positive results and a 98% agreement rate for negative results compared to the Hologic Panther Fusion.

LHDX

NASDAQ:LHDX

LHDX Rankings

LHDX Latest News

LHDX Stock Data

18.36M
30.26M
10.13%
23.9%
1.67%
Medical Devices
Healthcare
Link
United States
EmeryVille